Drug Profile
SCB 333
Alternative Names: SCB-333Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Clover Biopharmaceuticals
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Cancer in China
- 28 Dec 2017 Clover Biopharmaceuticals in-licenses Trimer-Tag© technology from GenHunter Corporation worldwide (Clover Biopharmaceuticals website, December 2017)
- 28 Dec 2017 SCB 333 is available for licensing as of 28 Dec 2017. http://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=44